Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cryoablation + PD-1 inhibitor + GC chemotherapy in unresectable advanced biliary tract tumors
ChiCTR2600127556Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jul 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tislelizumab, gemcitabine and cisplatin in biliary cancer, intrahepatic cholangiocarcinoma (ICC), hilar cholangiocarcinoma (HC) and 2 more, sponsored by West China Hospital of Sichuan University. Primary endpoint: Progression-free survival (PFS). Planned start Jul 2026; status: not yet recruiting.
02
Drugs
tislelizumabgemcitabinecisplatin
03
Conditions
biliary cancerintrahepatic cholangiocarcinoma (ICC)hilar cholangiocarcinoma (HC)distal cholangiocarcinoma (dCCA)gallbladder cancer
Beyond the preview
Go deeper on ChiCTR2600127556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127556.